Analysts’ Recent Ratings Changes for First Tracks Biotherapeutics (TRAX)

Several analysts have recently updated their ratings and price targets for First Tracks Biotherapeutics (NASDAQ: TRAX):

• 9/30/2026 – First Tracks Biotherapeutics is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $50.00 price target on the stock.
• 9/18/2026 – First Tracks Biotherapeutics is now covered by Evercore Inc. They set an “outperform” rating and a $65.00 price target on the stock.
• 9/18/2026 – First Tracks Biotherapeutics is now covered by Evercore Inc. They set an “outperform” rating and a $65.00 price target on the stock.
• 9/16/2026 – First Tracks Biotherapeutics is now covered by Guggenheim. They set a “buy” rating and a $100.00 price target on the stock.
• 9/16/2026 – First Tracks Biotherapeutics is now covered by UBS Group AG. They set a “buy” rating on the stock.
• 9/16/2026 – First Tracks Biotherapeutics is now covered by Guggenheim. They set a “buy” rating and a $100.00 price target on the stock.
• 9/16/2026 – First Tracks Biotherapeutics is now covered by Guggenheim. They set a “buy” rating and a $100.00 price target on the stock.
• 9/5/2026 – First Tracks Biotherapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/3/2026 – First Tracks Biotherapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $57.00 price target on the stock.
• 8/18/2026 – First Tracks Biotherapeutics is now covered by Wolfe Research. They set an “outperform” rating and a $83.00 price target on the stock.
• 8/13/2026 – First Tracks Biotherapeutics is now covered by Weiss Ratings. They set a “sell (d)” rating on the stock.
• 8/13/2026 – First Tracks Biotherapeutics had its price target raised by Piper Sandler from $54.00 to $95.00. They now have an “overweight” rating on the stock.
• 8/13/2026 – First Tracks Biotherapeutics had its price target raised by HC Wainwright from $44.00 to $57.00. They now have a “buy” rating on the stock.
• 8/13/2026 – First Tracks Biotherapeutics had its price target raised by Barclays PLC from $48.00 to $65.00. They now have an “overweight” rating on the stock.
• 8/13/2026 – First Tracks Biotherapeutics had its price target raised by Wedbush from $60.00 to $70.00. They now have an “outperform” rating on the stock.
• 8/10/2026 – First Tracks Biotherapeutics had its price target raised by UBS Group AG from $45.00 to $65.00. They now have a “buy” rating on the stock.

Insider Buying and Selling

In other First Tracks Biotherapeutics news, Director J. Ware sold 39,265 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $44.78, for a total value of $1,758,286.70. Following the completion of the sale, the director owned 15,660 shares in the company, valued at approximately $701,254.80. This trade represents a 71.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.